“While the jury’s $130 million verdict is significant and may sound large in the abstract, it may not be enough without enhancement to deter infringing conduct given the context of this case,” Judge Olguin wrote. Evidence presented at trial shows that the infringing products sold by Cochlear generated $1.8 billion in revenues. Cochlear had publicly stated in a 2016 annual report that the jury’s verdict won’t disrupt Cochlear’s business or U.S. customers.
The post Judge Awards Enhancement of Damages to $268 Million in Cochlear Implant Patent Case appeared first on IPWatchdog.com | Patents & Patent Law.
Recent Posts
- CAFC: Jury Instructions Must Address Each Objective Indicia of Nonobviousness Raised by Patent Owner
- Massive Replication of Comments Submitted to NIST March-In Rights RFI Should Cause Concern
- Lourie Dissents from CAFC View that Heart Valve Transport was Not Infringing
- Rader’s Ruminations – Patent Eligibility II: How the Supreme Court Ignored Statute and Revived Its Innovation-Killing Two-Step
- Other Barks and Bites for Friday, March 22: French Watchdog Hits Google with €250 Million for IP Breaches; C4IP Releases First Congressional Innovation Scorecard; EPO Sees Record Number of Patent Applications